Literature DB >> 19130186

Comparing models for perfluorooctanoic acid pharmacokinetics using Bayesian analysis.

John F Wambaugh1, Hugh A Barton, R Woodrow Setzer.   

Abstract

Selecting the appropriate pharmacokinetic (PK) model given the available data is investigated for perfluorooctanoic acid (PFOA), which has been widely analyzed with an empirical, one-compartment model. This research examined the results of experiments [Kemper R. A., DuPont Haskell Laboratories, USEPA Administrative Record AR-226.1499 (2003)] that administered single oral or iv doses of PFOA to adult male and female rats. PFOA concentration was observed over time; in plasma for some animals and in fecal and urinary excretion for others. There were four rats per dose group, for a total of 36 males and 36 females. Assuming that the PK parameters for each individual within a gender were drawn from the same, biologically varying population, plasma and excretion data were jointly analyzed using a hierarchical framework to separate uncertainty due to measurement error from actual biological variability. Bayesian analysis using Markov Chain Monte Carlo (MCMC) provides tools to perform such an analysis as well as quantitative diagnostics to evaluate and discriminate between models. Starting from a one-compartment PK model with separate clearances to urine and feces, the model was incrementally expanded using Bayesian measures to assess if the expansion was supported by the data. PFOA excretion is sexually dimorphic in rats; male rats have bi-phasic elimination that is roughly 40 times slower than that of the females, which appear to have a single elimination phase. The male and female data were analyzed separately, keeping only the parameters describing the measurement process in common. For male rats, including excretion data initially decreased certainty in the one-compartment parameter estimates compared to an analysis using plasma data only. Allowing a third, unspecified clearance improved agreement and increased certainty when all the data was used, however a significant amount of eliminated PFOA was estimated to be missing from the excretion data. Adding an additional PK compartment reduced the unaccounted-for elimination to amounts comparable to the cage wash. For both sexes, an MCMC estimate of the appropriateness of a model for a given data type, the Deviance Information Criterion, indicated that this two-compartment model was better suited to describing PFOA PK. The median estimate was 142.1 +/- 37.6 ml/kg for the volume of the primary compartment and 1.24 +/- 1.1 ml/kg/h for the clearances of male rats and 166.4 +/- 46.8 ml/kg and 30.3 +/- 13.2 ml/kg/h, respectively for female rats. The estimates for the second compartment differed greatly with gender-volume 311.8 +/- 453.9 ml/kg with clearance 3.2 +/- 6.2 for males and 1400 +/- 2507.5 ml/kg and 4.3 +/- 2.2 ml/kg/h for females. The median estimated clearance was 12 +/- 6% to feces and 85 +/- 7% to urine for male rats and 8 +/- 6% and 77 +/- 9% for female rats. We conclude that the available data may support more models for PFOA PK beyond two-compartments and that the methods employed here will be generally useful for more complicated, including PBPK, models.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19130186     DOI: 10.1007/s10928-008-9108-2

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  27 in total

1.  Assessing convergence of Markov chain Monte Carlo simulations in hierarchical Bayesian models for population pharmacokinetics.

Authors:  Michael G Dodds; Paolo Vicini
Journal:  Ann Biomed Eng       Date:  2004-09       Impact factor: 3.934

2.  How vague is vague? A simulation study of the impact of the use of vague prior distributions in MCMC using WinBUGS.

Authors:  Paul C Lambert; Alex J Sutton; Paul R Burton; Keith R Abrams; David R Jones
Journal:  Stat Med       Date:  2005-08-15       Impact factor: 2.373

3.  Diazepam pharamacokinetics from preclinical to phase I using a Bayesian population physiologically based pharmacokinetic model with informative prior distributions in WinBUGS.

Authors:  Ivelina Gueorguieva; Leon Aarons; Malcolm Rowland
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-06-29       Impact factor: 2.745

4.  Parameter and structural identifiability concepts and ambiguities: a critical review and analysis.

Authors:  C Cobelli; J J DiStefano
Journal:  Am J Physiol       Date:  1980-07

5.  Quantitative evaluation of alternative mechanisms of blood and testes disposition of di(2-ethylhexyl) phthalate and mono(2-ethylhexyl) phthalate in rats.

Authors:  D A Keys; D G Wallace; T B Kepler; R B Conolly
Journal:  Toxicol Sci       Date:  1999-06       Impact factor: 4.849

6.  Tissue distribution, metabolism, and elimination of perfluorooctanoic acid in male and female rats.

Authors:  J P Vanden Heuvel; B I Kuslikis; M J Van Rafelghem; R E Peterson
Journal:  J Biochem Toxicol       Date:  1991

Review 7.  Perfluoroalkyl acids: a review of monitoring and toxicological findings.

Authors:  Christopher Lau; Katherine Anitole; Colette Hodes; David Lai; Andrea Pfahles-Hutchens; Jennifer Seed
Journal:  Toxicol Sci       Date:  2007-05-22       Impact factor: 4.849

8.  Roles of organic anion transporters in the renal excretion of perfluorooctanoic acid.

Authors:  Hatsuki Nakagawa; Taku Hirata; Tomohiro Terada; Promsuk Jutabha; Daisaku Miura; Kouji H Harada; Kayoko Inoue; Naohiko Anzai; Hitoshi Endou; Ken-Ichi Inui; Yoshikatsu Kanai; Akio Koizumi
Journal:  Basic Clin Pharmacol Toxicol       Date:  2008-07-01       Impact factor: 4.080

9.  Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1980-12

10.  Polyfluoroalkyl chemicals in the U.S. population: data from the National Health and Nutrition Examination Survey (NHANES) 2003-2004 and comparisons with NHANES 1999-2000.

Authors:  Antonia M Calafat; Lee-Yang Wong; Zsuzsanna Kuklenyik; John A Reidy; Larry L Needham
Journal:  Environ Health Perspect       Date:  2007-11       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.